Scope Biosciences Secured CE Mark for Fungal Test
The eazySNP test detects echinocandin-resistant mutations in Candida auris to guide clinical treatment decisions.
Updated on Oct. 14, 2026 in Life Sciences
Live Poll
Should medical providers prioritize adopting rapid CRISPR-based diagnostic tests over traditional laboratory methods?
Scope Biosciences has received a CE mark for its eazySNP C. auris FKS1 S639 diagnostic test. The device provides a rapid way to identify specific genetic mutations in the pathogen.
Why it matters
The test helps clinicians identify Candida auris infections that are resistant to echinocandins. Because these drugs are standard treatments, rapid identification of resistance prevents the use of ineffective therapies.
The eazySNP assay utilizes a combination of isothermal DNA amplification and CRISPR detection. It requires a yeast colony to operate on the eazyMini instrument, delivering a final result in 45 minutes.
The players
Scope Biosciences
This biotechnology company focuses on developing diagnostic platforms that integrate CRISPR technology.
AmplexDiagnostics GmbH
This firm specializes in the development and manufacturing of molecular diagnostic tools and testing equipment.
The details
Developed alongside AmplexDiagnostics GmbH, the test is now compliant under the European Union's In Vitro Diagnostic Medical Devices Regulation. It specifically screens for the FKS1 S639 mutation, which renders the yeast resistant to frontline antifungal medication.
Timeline
October 14, 2026: The diagnostic test officially received its CE mark.
The Big Picture
The authorization of this tool follows the strict safety and performance standards mandated by the EU's In Vitro Diagnostic Medical Devices Regulation. This certification validates the use of CRISPR-based diagnostics in clinical settings, bridging a gap between laboratory research and diagnostic practice.
This rapid diagnostic capability allows healthcare providers to quickly pivot to effective treatment protocols for resistant infections. Faster identification reduces the reliance on ineffective medication, potentially improving patient outcomes and hospital infection control.
The takeaway
Rapid diagnostic tools like the eazySNP are essential for managing modern drug-resistant pathogens. Medical facilities should prioritize early testing to ensure patients receive appropriate treatment before infections escalate.
Further reading
Learn more about the latest innovations in clinical diagnostics within the Life Sciences.
Source note: This article includes information reported by Scientist Live.
Live Poll
Should medical providers prioritize adopting rapid CRISPR-based diagnostic tests over traditional laboratory methods?
